Related Experiment Video
Updated: Feb 14, 2026
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Clinical Features of Machado-Joseph Disease
Nuno Mendonça1,2, Marcondes C França3, António Freire Gonçalves2,4
1CNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal.
Abstract:
Machado-Joseph disease (MJD) also known as Spinocerebellar ataxia type 3, is a hereditary neurodegenerative disease associated with severe clinical manifestations and premature death. Although rare, it is the most common autosomal dominant spinocerebellar ataxia worldwide and has a distinct geographic distribution, reaching peak prevalence in certain regions of Brazil, Portugal and China. Due to its clinical heterogeneity, it was initially described as several different entities and as had many designations over the last decades. An accurate diagnosis become possible in 1994, after the identification of the MJD1 gene. Among its wide clinical spectrum, progressive cerebellar ataxia is normally present. Other symptoms include pyramidal syndrome, peripheral neuropathy, oculomotor abnormalities, extrapyramidal signs and sleep disorders. On the basis of the presence/absence of important extra-pyramidal signs, and the presence/absence of peripheral signs, five clinical types have been defined. Neuroimaging studies like MRI, DTI and MRS, can be useful as they can characterize structural and functional differences in specific subgroups of patients with MJD. There is no effective treatment for MJD. Symptomatic therapies are used to relieve some of the clinical symptoms and physiotherapy is also helpful in improving quality of live. Several clinical trials have been carried out using different molecules like sulfamethoxazole-trimethoprim, varenicline and lithium carbonate, but the results of these trials were negative or showed little benefit. Future studies sufficiently powered and adequately designed are warranted.
Insights
Machado-Joseph disease (MJD), or Spinocerebellar ataxia type 3, is a rare, inherited neurodegenerative disorder. Current treatments offer only symptomatic relief, and clinical trials have yielded limited benefits, necessitating further research.
Area of Science:
- Neuroscience
- Genetics
- Neurology
Background:
- Machado-Joseph disease (MJD), also known as Spinocerebellar ataxia type 3, is a rare, autosomal dominant neurodegenerative disorder.
- It is the most common spinocerebellar ataxia globally, with notable prevalence in specific regions of Brazil, Portugal, and China.
- The identification of the MJD1 gene in 1994 enabled accurate diagnosis, despite the disease's initial description under various names due to clinical heterogeneity.
Purpose of the Study:
- To provide a comprehensive overview of Machado-Joseph disease (MJD), encompassing its genetic basis, clinical spectrum, diagnostic approaches, and current therapeutic limitations.
- To highlight the role of neuroimaging in characterizing MJD subtypes.
- To underscore the need for future research into effective treatments.
Main Methods:
- Review of existing literature on Machado-Joseph disease (MJD).
- Analysis of clinical manifestations, genetic findings, and diagnostic criteria.
- Examination of neuroimaging techniques (MRI, DTI, MRS) for MJD patient subgroup characterization.
- Evaluation of outcomes from past clinical trials for MJD therapies.
Main Results:
- MJD presents with progressive cerebellar ataxia, often accompanied by pyramidal syndrome, peripheral neuropathy, oculomotor abnormalities, extrapyramidal signs, and sleep disorders.
- Five distinct clinical types of MJD have been defined based on the presence of extra-pyramidal and peripheral signs.
- Neuroimaging studies can differentiate structural and functional changes in MJD subgroups.
- Previous clinical trials using sulfamethoxazole-trimethoprim, varenicline, and lithium carbonate showed minimal or no benefit.
Conclusions:
- Machado-Joseph disease (MJD) is a severe, inherited neurodegenerative disorder with no effective cure.
- Symptomatic treatments and physiotherapy can improve quality of life.
- Further well-powered and adequately designed clinical studies are essential to develop effective therapies for MJD.
Related Concept Videos
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:30Toxidromes: Clinical Features
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:26Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
01:25Endocarditis II: Clinical Features of Infective Endocarditis
01:19Pericarditis II: Clinical Features and Diagnostic Tests